Flash Finance

Eris Lifesciences LimitedERISCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,144.40
MCap ₹15,859 Cr · P/E 23.8
Eris Lifesciences Limited — Stock analysis & AI research Eris Lifesciences Limited — Multibagger AI analysis Eris Lifesciences Limited — Seasonality — best & worst months Eris Lifesciences Limited — Technical indicators & charts Eris Lifesciences Limited — Technical setup — score, trend, support & resistance Eris Lifesciences Limited — Falling Wedge pattern forming Eris Lifesciences Limited — Live exchange announcements
📋 High Operating Margin Stocks📋 Stocks Cheaper Than Their Industry📋 Small Cap Stocks List 📈 RSI Oversold Stocks📈 New 52-Week Low Stocks📈 Lowest Technical Score📈 Multi-Timeframe Bearish Stocks📈 Stocks Near 52-Week Low 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹873 Cr
Sales · Jun 2026
+13.0% YoY
₹296 Cr
Operating Profit · Jun 2026
+7.1% YoY
33.9%
OPM % · Jun 2026
-5.3% YoY
₹143 Cr
Net Profit · Jun 2026
+14.6% YoY
₹10.28
EPS · Jun 2026
+18.7% YoY

📝 Eris Lifesciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Eris Lifesciences Limited reported revenue of ₹873 crore for the quarter ended June 2026 (Q1 FY27), up 13.0% from ₹773 crore in the same quarter last year, and up 15.4% sequentially over the March 2026 quarter.

Net profit rose 14.6% year-on-year to ₹143 crore, from ₹125 crore. Earnings per share (EPS) came in at ₹10.28.

Operating profit stood at ₹296 crore — an operating margin (OPM) of 33.9%, compared with 35.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Eris Lifesciences Limited posted revenue of ₹3,130 crore, a growth of 8.2% over FY25, with a net profit of ₹647 crore (up 72.6% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹3,230 crore with a net profit of ₹666 crore.

Valuation snapshot

At the current price of ₹1,144.40, ERIS has a market capitalisation of ₹15,859 crore and a trailing P/E of about 23.8.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 24th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 54.14%, foreign institutional investors (FIIs) 5.75%, domestic institutional investors (DIIs) 20.72%, public shareholders 19.40% of Eris Lifesciences Limited.

Promoter holding rose from 53.92% to 54.14% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹15,859 Cr
Current Price ?
₹1,144.4
P/E ?
23.83below ind
Industry P/E ?
35.00
P/B ?
4.06
P/S ?
4.91
P/FCF ?
65.81
Enterprise Value ?
₹18,218 Cr
EV/EBITDA ?
16.01
PEG ?
1.25
Earnings Yield ?
4.7%
Dividend Yield ?
0.63%
Profitability & Returns
Sales (TTM) ?
₹3,230 Cr
OPM ?
35.2%
Profit after tax (TTM) ?
₹666 Cr
EPS (TTM) ?
₹48.03
ROCE ?
14.0%
ROE ?
17.1%
ROA ?
9.0%
Growth
Sales — latest qtr ?
₹873 Cr
PAT — latest qtr ?
₹143 Cr
YoY qtr sales growth ?
13.0%
YoY qtr profit growth ?
14.6%
Sales growth (3y) ?
23%
Sales growth (5y) ?
21%
Profit growth (3y) ?
19%
Profit growth (5y) ?
12%
Financial Health
Debt ?
₹2,359 Cr
Debt to Equity ?
0.60
Interest Coverage ?
4.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
54.14%
Change in promoter holding ?
-0.69%
Pledged percentage ?
N/A
Market
Return 3 months ?
-21.4%
Return 6 months ?
-20.8%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 423403467505486551720741727705773792807757873 +13.0% +15.4%
Operating Profit 137119170181176148250265250252277288282272296 +7.1% +8.9%
Other Income 2113415254833022 -11.2% +19.5%
Interest 3917161833605957544950494647 -4.2% +1.4%
Depreciation 303541424654768081777169707072 +2.2% +3.0%
Profit Before Tax 1077611212611677115129116129161173145159179 +11.4% +12.9%
Net Profit 100619412210180899687102125134109279143 +14.6% -48.6%
EPS 7.494.816.979.087.555.226.116.736.156.908.668.827.3220.3310.28 +18.7% -49.4%
OPM % 32.4% 29.5% 36.4% 35.8% 36.1% 26.9% 34.7% 35.7% 34.4% 35.8% 35.8% 36.4% 34.9% 35.9% 33.9% -5.3% -5.6%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹2,894 Cr ₹3,130 Cr ₹3,230 Cr +8.2%
Operating Profit ₹1,017 Cr ₹1,119 Cr ₹1,138 Cr +10.0%
OPM % 35.15% 35.74% 35.23% +1.7%
NPM % 12.96% 20.68% 20.61% +59.6%
Other Income ₹18 Cr ₹8 Cr ₹7 Cr -59.0%
Depreciation ₹315 Cr ₹280 Cr ₹281 Cr -11.1%
Interest ₹231 Cr ₹193 Cr ₹191 Cr -16.5%
EBIT ₹702 Cr ₹839 Cr ₹857 Cr +19.4%
PBT ₹489 Cr ₹638 Cr ₹657 Cr +30.4%
Tax ₹114 Cr ₹111 Cr ₹111 Cr -3.2%
Net Profit ₹375 Cr ₹647 Cr ₹666 Cr +72.6%
EPS ₹25.89 ₹45.13 ₹46.75 +74.3%
Material Cost ₹749 Cr ₹626 Cr ₹677 Cr -16.5%
Employee Cost ₹505 Cr ₹420 Cr ₹429 Cr -16.9%
Extraordinary Items — ₹17 Cr ₹17 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 14141414 +0.0%
Reserves 2,1822,5732,8413,889 +36.9%
Borrowings 8772,7812,4782,359 -4.8%
Other Liabilities 3371,3661,4121,104 -21.8%
Total Liabilities 3,4106,7346,7447,366 +9.2%
Fixed Assets 2,5684,3195,3065,188 -2.2%
CWIP 222067171 +155.2%
Investments 37166762 -7.5%
Other Assets 7832,3791,3041,945 +49.2%
Total Assets 3,4106,7346,7447,366 +9.2%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 2924861,065538 -49.5%
Cash from Investing Activity -975-1,828-78-369 -373.1%
Cash from Financing Activity 6881,380-881-314 +64.4%
Net Cash Flow 538105-145 -238.1%
Free Cash Flow -550357910241 -73.5%
CFO/OP 68%87%114%59% -48.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 63775879 +36.2%
Inventory Days 136182171200 +17.0%
Days Payable 129210170151 -11.2%
Cash Conversion Cycle 704859129 +118.6%
Working Capital Days 50-296-49-71 -44.9%
ROCE % 17%11%12%14% +16.7%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 54.83%54.85%54.85%53.92%54.14% +0.4%
FIIs 8.39%7.21%6.85%6.39%5.75% -10.0%
DIIs 18.18%19.36%20.31%20.35%20.72% +1.8%
Public 18.59%18.57%17.97%19.33%19.40% +0.4%
No. of Shareholders 52,22559,43854,71351,65650,798 -1.7%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Eris Lifesciences Limited's revenue in Q1 FY27?
Eris Lifesciences Limited reported revenue of ₹873 crore for the quarter ended June 2026 (Q1 FY27), up 13.0% from ₹773 crore in the same quarter last year, and up 15.4% sequentially over the March 2026 quarter.
What was Eris Lifesciences Limited's net profit in Q1 FY27?
Net profit rose 14.6% year-on-year to ₹143 crore, from ₹125 crore. Earnings per share (EPS) came in at ₹10.28.
What is ERIS's market capitalisation and P/E ratio?
At the current price of ₹1,144.40, ERIS has a market capitalisation of ₹15,859 crore and a trailing P/E of about 23.8.
Who owns Eris Lifesciences Limited? (shareholding pattern)
As of Jun 2026, promoters held 54.14%, foreign institutional investors (FIIs) 5.75%, domestic institutional investors (DIIs) 20.72%, public shareholders 19.40% of Eris Lifesciences Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI